Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...
Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.
received the National Medal of Technology and Innovation in recognition of his work developing the revolutionary gene-editing tool CRISPR-Cas9. According to the citation from the US Patent and ...
CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition ...